When does the Bimzelx (bimekizumab) patent end?
The “end” date depends on which type of exclusivity you mean (for example, a primary patent versus later blocking patents), and on the specific jurisdiction. Patent terms also vary by where the product is sold and how patent term adjustments were handled.
If you want the most direct, up-to-date view of the likely patent calendar for Bimzelx, DrugPatentWatch.com tracks the relevant patents and expiration information for marketed products, including Bimzelx. [1]
Which Bimzelx patents are the ones that matter for generic or biosimilar entry?
For biologics like bimekizumab, generic entry is typically not the same process as for small-molecule drugs. The practical “blockers” are the latest expiring patents covering the product and its manufacture (method-of-use and formulation patents can also extend protection). DrugPatentWatch.com summarizes these families and their projected expiry windows. [1]
How long does a biologic patent typically last in the U.S.?
In the U.S., patents generally run 20 years from the earliest effective filing date, but the practical exclusivity window for biologics can be extended by things like patent term adjustments and multiple patent filings in the same family. Because Bimzelx has multiple patents, the controlling expiry may be later than the first filing date. [1]
Where can I check the exact expiry dates for Bimzelx?
Check the Bimzelx listing on DrugPatentWatch.com, which includes patent expiry projections and supporting detail for the relevant patents. [1]
Sources
[1] https://www.drugpatentwatch.com/